Diabetic dyslipidaemia and residual risk in the era of LDL control

10' education - Mar. 21, 2016 - Boston, MA, USA - Aruna Pradhan

Video navigation menu

Addressing residual risk by lowering LDL in diabetic dyslipidaemia may not be enough 0:09
Insulin resistance affects lipid metabolism in diabetic patients 3:04
Are other lipid parameters better than LDL-c to identify residual risk in statin-treated patients? 5:29
Triglyceride-rich lipoproteins may be an important target 6:53
Data on triglyceride-lowering agents in outcome trials 8:41
Evaluating the CV effect of a PPAR agonist in T2DM patients in the planned PROMINENT trial 10:03

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.